Biotech news for Tuesday, June 23, 2026, ranked by our 5-dimension investment framework — regulatory, technology, commercial, manufacturing, and narrative.
Thomas Barwick Apogee Therapeutics ( APGE ) shares surged by as much as 56% in premarket trading on Monday after the Financial Times reported that AbbVie ( ABBV ) is close to acquiring the company in a deal valued at nearly $11B, strengthening
ojos de hojalata/iStock via Getty Images MoonLake Immunotherapeutics ( MLTX ) on Sunday said its experimental drug sonelokimab delivered strong one-year results in two Phase 3 trials for hidradenitis suppurativa, a chronic inflammatory skin disease that causes…
Michael Vi/iStock Editorial via Getty Images AbbVie ( ABBV ) is approaching a nearly $11B agreement to buy anti-inflammatory drug developer Apogee Therapeutics ( APGE ), in a deal expected to become the pharma giant’s largest bolt-on acquisition since 2019, Th…
Md Ariful Islam/iStock via Getty Images A US FDA advisory panel unanimously agreed that the benefits of Moderna's ( MRNA ) mRNA seasonal flu vaccine, mRNA-1010, outweigh the risks in individuals 50-75 years old. The agency's Vaccines and Related Biological Pro…
AbbVie ( ABBV ) declares $1.73/share quarterly dividend , in line with previous. Forward yield 3.19% Payable Aug. 14; for shareholders of record July 15; ex-div July 15. See ABBV Dividend Scorecard, Yield Chart, & Dividend Growth. More on AbbVie AbbVie: Ma…
RBC Capital Markets has initiated Praxis Precision Markets at outperform, saying that a recent pullback provides a good entry point, adding they "expect a transformative next six months." The firm has a $449 price target (~66% upside based on June 17 close).
Silo Pharma ( SILO ) on Thursday said it regained compliance with Nasdaq's minimum bid price requirement as of June 17. The developmental-stage biopharmaceutical company said its shares will continue trading on the Nasdaq Capital Market and that the compliance…